News
July 12, 2022
CEO Dr. Igor Sherman Featured in CEOCFO Magazine



May 26, 2022
Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, in Online Publication at the 2022 American Society of Clinical Oncology Annual Meeting
Press Release
In a COLO-205 xenograft model, ACT-903 demonstrates tumor suppression, increased survival after single and multiple doses, and no signs of toxicityToronto, Canada, May 26, 2022 — Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, announced details from the company’s abstract published today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO meeting will be held in Chicago from June 3-8, 2022.
View Full Press Release
April 15, 2022
Alpha Cancer Technologies Inc. Announces Acceptance of Abstract for Online Publication at the 2022 American Society of Clinical Oncology Annual Meeting
Press Release
Abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022Toronto, Canada, April 14, 2022 — Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that an abstract the company submitted has been accepted by American Society of Clinical Oncology (ASCO) for the 2022 ASCO Annual Meeting and will be published in an online supplement of the Journal of Clinical Oncology following the meeting. ASCO will be held in Chicago from June 3-8, 2022.
This year, ASCO received and reviewed more than 6,000 abstracts for the 2022 ASCO Annual Meeting. For more information about the Annual Meeting, please visit:
https://conferences.asco.org/am/attend. Per ASCO’s Embargo & Release Information, abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022.
September 16, 2021
Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
Preclinical studies show ACT-903 demonstrates tumor suppression, increased survival, maytansine and metabolite accumulation in the tumor, and no signs of toxicity
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced the presentation of new preclinical data from the Company’s investigational therapy, ACT-903 at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.
View Full Press Release
View Poster
August 17, 2021
AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein platform, today announced that its abstract featuring data from the Company’s investigational therapy, ACT-903, has been selected for presentation at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.
Details about the abstract selected for poster publication can be found below:
Title: AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Abstract Number: 523P
Authors: I. Sherman, R. Boohaker, K. Stinson, P. Griffin, W. Hill
Abstracts are under embargo until 5:00 p.m. ET on Sept. 15, 2021.
For more information about the Annual Meeting, please visit: https://www.esmo.org/meetings/esmo-congress-2021